The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer

NCT01023802 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2013-05-10

No results posted yet for this study

Summary

In patients with breast cancer who undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy molecular breast imaging (MBI) is an accurate test for assessing response rate to neoadjuvant therapy.

Conditions

  • Neoadjuvant Therapy
  • Chemotherapy
  • Hormone Replacement Therapy
  • Breast Cancer

Sponsors & Collaborators

Principal Investigators

  • Dietlind L. Wahner-Roedler, M.D. · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01023802 on ClinicalTrials.gov